Trial Profile
Cellular immunity after alemtuzumab - ZINA
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ZINA
- 05 Nov 2018 Status changed from not yet recruiting to recruiting.
- 08 Mar 2017 New trial record